deltatrials
Completed PHASE3 NCT00035789

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

Sponsor: Bristol-Myers Squibb

Conditions Chronic Hepatitis B
Interventions Entecavir
Updated 7 times since 2017 Last updated: Apr 7, 2011 Started: Nov 30, 2001 Primary completion: May 31, 2005 Completion: May 31, 2005

Listed as NCT00035789, this PHASE3 trial focuses on Chronic Hepatitis B and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 7 times since 2001, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Nov 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States, Atlanta, United States, Birmingham, United States, Charlotte, United States, Chicago, United States, Cleveland, United States, Dallas, United States, Dundalk, United States, Fairfax, United States, Farmington, United States and 21 more location s